Viracta Therapeutics (VIRX) Announces CFO and COO Resignation

On March 15, 2024, Dan Chevallard informed Viracta Therapeutics (NASDAQ: VIRX) that he was resigning from his positions as Chief Financial Officer and Chief Operating Officer of the Company, effective on March 20, 2024, to pursue other opportunities. Mr. Chevallard’s resignation is voluntary and is not the result of any disagreement with the Company related to its operations, policies, or practices. The Company thanks Mr. Chevallard for his many contributions to the Company over the last four years, eight months. As set forth below, in connection with Mr. Chevallard’s resignation, the Company entered into a consulting agreement with Mr. Chevallard pursuant to which he will provide certain transition services to the Company.

Effective upon Mr. Chevallard’s resignation as Chief Financial Officer and Chief Operating Officer, Melody Burcar, the Company’s Senior Vice President of Finance, will serve as the Company’s interim principal financial officer and interim principal accounting officer while the Company engages in a search for a permanent replacement for Mr. Chevallard.

You May Also Be Interested In

• Zscaler to cut 3% staff
• Cloudflare launches AI vulnerability service with OpenAI
• investor plans to vote against Angel Oak fund trustee nominees